Discount or Validation? The Shifting Economics of Western Pharma's Licensing of Chinese Assets
核心洞察
Average upfront payments by Western buyers for Chinese biotech assets have climbed roughly 230% from about $52 million in 2022 to around $172 million in early 2026.
Chinese drugmakers now account for roughly half of all global out-licensing deals by count, with disclosed 2025 value estimated near $136 billion across approximately 157 transactions.
The origin discount is shrinking as competition intensifies, particularly for assets with multiregional clinical data that meet ICH E17 standards, though single-geography data still carries regulatory risk.
The average upfront paid by a Western buyer to license a molecule from a Chinese biotech has climbed roughly 230 percent in four years, from about $52 million in 2022 to around $172 million in early 2026. Over the same stretch, Chinese drugmakers went from a rounding error in global out-licensing to signing something on the order of half of all such deals by count, with disclosed 2025 value estimated near $136 billion across roughly 157 transactions. In the first quarter of 2026 alone, cross-border out-licensing out of China reportedly crossed $60 billion.
Those numbers are not in dispute. What they mean is where the argument lives.
The Two Framings
The buyer's framing is that a discount, where it exists, is rational. A clinical-stage asset from anywhere is mostly a bundle of unresolved questions, and a molecule whose pivotal evidence sits in a single geography carries a specific, nameable risk: that a Western regulator will want data it does not yet have. Price that risk, the argument goes, and the so-called China discount is not a discount at all — it is the market doing its job.
The seller's framing is that the haircut is applied first and rationalized second. On this reading, comparable Western assets at the same stage, with data no stronger, command larger upfronts and richer total packages, and the difference tracks origin rather than evidence. The data-quality concern, sellers argue, is a story buyers tell to justify a price they were going to offer regardless.
The Marquee Deals
Across the window from the start of 2024 through the first half of 2026, the marquee transactions share a recognizable shape: a modest-to-large upfront, an equity component in a growing minority of cases, and a very large stack of contingent milestones that dwarfs the cash paid at signing.
In late 2024, Merck (搜索) agreed to pay $588 million upfront for a Phase 1 PD-1 (搜索) by VEGF (搜索) bispecific from Shanghai-based LaNova Medicines (搜索), against roughly $2.7 billion in potential milestones. In 2025, Pfizer paid 3SBio (搜索) $1.25 billion upfront, took a $100 million equity stake, and layered on as much as $4.8 billion in milestones for ex-China rights to a competing PD-1 by VEGF bispecific. GSK committed $500 million upfront to Jiangsu Hengrui (搜索) for a COPD candidate plus options on eleven further programs, a package that reaches roughly $12 billion if the portfolio delivers. Regeneron struck a potential $2 billion pact for a GLP-1 (搜索) by GIP (搜索) agonist from Hansoh (搜索). And in early 2026, AstraZeneca signed an obesity and diabetes deal with CSPC (搜索) carrying a $1.2 billion upfront and a headline value reported as high as $18.5 billion.
Two structural features run through almost all of these transactions. First, the gap between cash-today and headline-value is enormous. In the GSK-Hengrui case, the upfront is barely four percent of the potential total. Second, the deals are getting more sophisticated on the sell side, with Chinese licensors increasingly carving territory finely and using the NewCo model to retain equity upside.
The Comparator Test
Chinese innovative assets have carried upfronts on the order of 60 to 70 percent below Western peers, with total deal sizes 40 to 50 percent smaller. For Phase II and later oncology assets, upfronts of $200 to $500 million are now common, and Chinese licensors have stopped accepting token upfronts in exchange for milestone-heavy packages.
The honest reading is that the gap is real, sizable, and shrinking. The 230 percent climb in average upfronts is the sound of the discount being competed away in plain view. When multiple buyers chase the same class, as they did across the PD-1 (搜索) by VEGF (搜索) bispecifics, the origin haircut narrows toward zero, because a buyer who insists on the old discount simply loses the asset to one who will not.
Mark Lansdell of Evaluate, whose firm produced the 230 percent figure, has argued that China can no longer be described as the bargain basement of biopharma licensing, and that dealmaking will continue even as prices rise because affordability was never the only reason the assets were attractive. Jefferies' Cui Cui has tracked the share of global out-licensing value originating in China from single digits, to 21 percent across 2023 and 2024, to 32 percent by the first half of 2025.
Testing the Data Quality Question
The discount's official justification is data quality, and the record is genuinely mixed. The cautionary case has a name: sintilimab. The PD-1 (搜索) inhibitor was approved in China but rejected by the FDA in 2022, because its pivotal evidence rested on a trial run exclusively in China and did not, in the agency's view, reflect the diversity of the US population or benchmark against a US-approved comparator on the endpoint that mattered.
The validation case is that Chinese sponsors read the sintilimab signal and changed their behavior. China joined ICH in 2017 and adopted the E17 multiregional-trial framework, and by 2024 the majority of pivotal trials in the country were multiregional. One published analysis of multiregional trials involving Chinese populations found that every one of the programs that reached the application stage went on to approval. NMPA has moved to compress its clinical-trial review clock toward the FDA's 30-day standard.
The label "Chinese-origin" has stopped predicting data quality with any reliability, which means using it as a pricing shortcut is now a bet, not a fact.
The Seller's Position
The intuitive forced-seller thesis — that a brutal funding winter left Chinese biotechs starved of capital — has aged badly. Through 2022 and 2023 it was largely accurate, but by 2025 the door had swung back. Hong Kong ranked first among global exchanges for IPO proceeds, with full-year totals around $37 billion, and biotech was a leading driver. Fourteen healthcare firms used the 18A pathway in 2025, and by late December thirteen biotechs had raised a combined $6.4 billion under 18A. The Hang Seng innovative-drug index climbed roughly 70 percent over the year.
The honest position holds both facts at once. The market is bifurcated. A well-capitalized, 18A-listed developer with a multiregional dataset negotiates from strength, keeps equity through a NewCo, and helps compress the origin discount toward nothing. A smaller, pre-revenue company staring at a lapsed prospectus and a cash crunch takes the upfront because it must, and the discount it accepts is at least partly the price of survival.
What the Answer Looks Like
The answer the evidence keeps pointing to is that it was both a discount and a validation, and the mix is shifting. There was a discount, and part of it was rational: single-geography data carried a real, sintilimab-shaped regulatory risk, and pricing that risk was not prejudice. Part of it was reputational: a haircut applied to origin that outlived the fast-follow reality it was built on, and that competition is now stripping out in real time. And part of it came from the seller's side of the table, from a funding environment that in 2022 and 2023 genuinely forced hands, and that by 2026 does so only for the weaker half of a bifurcated market.
The useful discipline is to ask, of any given transaction, which of the three forces is actually setting the price: the data, the reputation, or the seller's bank balance. On the best assets, the first is now the only one that survives scrutiny. On the rest, the argument is still open, and the money riding on it is getting larger every quarter.